u/kaia_kuusela

Went slowly because everything published describes a deliberate escalation. That is the extent of what I will say about it.

Reference intervals are typically the central 95% of a reference population. By construction one person in twenty falls outside one on any given test without anything being wrong.

Imaging-derived liver fat fraction is a surrogate. It correlates with histology imperfectly, and a trial reporting one is not reporting the other.

Histological endpoints in this field are scored on biopsy: resolution of steatohepatitis without worsening of fibrosis, or improvement in fibrosis without worsening of steatohepatitis. Both are harder to achieve and to interpret than an imaging surrogate.

Small fix — a reference interval is not a treatment target, and the post above uses them interchangeably.

My ferritin moved and I spent a fortnight convinced I knew why. The repeat six weeks later was back in range and I had changed nothing.

dual GLP-1 and glucagon agonist, and the glucagon arm is the story

research material is not approved for human use, which is why the clinical record here is thin

Has anyone posted an independent purity result for this compound?

That is a non-fasting value and the interval you are comparing it against is a fasting one.

Cosigning on baseline. The panel I regret most is the one I did not take before starting.

bring the numbers to someone qualified to read them

read the histology endpoint definitions before quoting a response rate

Adding the standing caveat — unapproved compound, research material is not for human use.

Same. Very thin independent data on this one, which should make everybody here more tentative than they are.

The escalation schedules in the published protocols are slow and deliberate, and the tolerability tables show why.

certified_reference is right that biopsy and imaging endpoints are not interchangeable.

Small fix — a reference interval is not a treatment target, and the post above uses them interchangeably.

Different laboratories use different assay platforms with different calibration. Comparing across labs adds a systematic offset that is invisible on the report.

a single eGFR outside range is a reason to repeat, not to panic

How many weeks between the two measurements?

Same view — ApoB if you add one thing. It answers a question the standard panel only gestures at.

Took a baseline the week before starting purely because this board told me to. Best five minutes I have spent on this.

Yes. Repeat before you react. Almost every alarming single value I have posted here regressed on the repeat.

Imaging-derived liver fat fraction is a surrogate. It correlates with histology imperfectly, and a trial reporting one is not reporting the other.

lab reference ranges are not treatment targets

I would not read across from the obesity programmes. Different population, different endpoint, different question.

This. Reference ranges are population intervals, not targets, and conflating them causes a lot of unnecessary alarm here.

MASH endpoints are histological, which is a much harder bar

Imaging-derived liver fat fraction is a surrogate. It correlates with histology imperfectly, and a trial reporting one is not reporting the other.

independent testing on this compound is very thin

Small fix — a reference interval is not a treatment target, and the post above uses them interchangeably.

I would not draw a line through two points, especially when the second was taken at a different time of day.

This is the sentence to read before anybody panics about a single value.

Small fix — a reference interval is not a treatment target, and the post above uses them interchangeably.

Tracked eGFR against the weight trend for a year. The correlation was much weaker than I expected and that was worth knowing.